A Medical Device Daily

Osteotech (Eatontown, New Jersey), a developer of biologic solutions for the field of regenerative medicine, reported that the United States Patent and Trademark Office has confirmed the validity of its U.S. Patent No. 5,676,146.

The '146 patent covers mixtures of a radiolucent material, such as demineralized bone, with a radiopaque material, such as nondemineralized or partially demineralized bone, that is provided in sufficient quantity to be used as a radiographic marker. The Patent Office's reexamination certificate also includes four new claims.

"The '146 patent is an important part of our strategic vision providing patent protection for certain of our current Grafton DBM products and for our next generation DBM products currently under development," said Sam Owusu–Akyaw, Osteotech's president/CEO. "It is our patent protection that allows us to make the investments necessary to continue to develop superior products for the medical community and patient care."

Osteotech provides solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of products that alleviate pain, promote biologic healing and restore function.